Arima Genomics Appoints Genomics Industry Veteran Tom Willis as Chief Executive Officer and Closes $22 Million Series C Financing

Arima Genomics任命基因组行业资深人士汤姆·威利斯为首席执行官，并完成2200万美元C轮融资。

Illumina Ventures leads round to accelerate Arima’s clinical expansion

Illumina Ventures领投，加速Arima的临床扩展

CARLSBAD, Calif., June 17, 2025--Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the appointment of Tom Willis, PhD, as chief executive officer and the close of a $22 million Series C financing led by Illumina Ventures.

加利福尼亚州卡尔斯巴德，2025年6月17日——Arima Genomics, Inc.是一家利用全基因组序列和结构信息提供全面癌症治疗选择见解的公司，今天宣布任命汤姆·威利斯博士为首席执行官，并完成了由Illumina Ventures领投的2200万美元C轮融资。

The round includes participation from genomics pioneers John Stuelpnagel and Mostafa Ronaghi, PhD, as well as existing backers Co-Win Ventures and Berkeley Catalyst Fund. The leadership transition and new capital mark a strategic pivot as Arima strengthens its focus on transforming oncology testing..

本轮融资包括基因组学先驱约翰·斯图尔普纳格尔和穆斯塔法·罗纳吉博士，以及现有支持者 Co-Win Ventures 和伯克利催化剂基金的参与。随着 Arima 加强对转化肿瘤学检测的关注，领导层过渡和新资本标志着一个战略转折。

“During my decade at Illumina Ventures, I evaluated countless genomics innovations, yet Arima’s approach stands out for its ability to illuminate aspects of the genome most tests never see,” said Willis. “I’m joining from the inside because I believe Arima is uniquely positioned to help save patients’ lives by enabling access to highly effective therapies today and new treatment paradigms going forward.”.

“在Illumina Ventures的十年里，我评估了无数基因组学创新，但Arima的方法因其能够揭示大多数测试无法看到的基因组方面而脱颖而出，”Willis表示。“我之所以从内部加入，是因为我相信Arima具备独特的优势，可以通过提供高效疗法的可及性来拯救患者生命，并推动未来新的治疗范式。”

Arima’s proprietary platform captures how DNA is organized inside the nucleus, uniting chromatin architecture with sequence data in a single readout. The technology is already reaching patients through the company’s CLIA-certified Aventa clinical testing laboratory, which routinely uncovers gene fusions and rearrangements overlooked by other clinical tests—insights that define diagnosis, prognosis and therapy selection across multiple cancers.

Arima的专有平台捕获了DNA在细胞核内的组织方式，将染色质结构与序列数据结合在单次读取中。该技术已经通过公司的CLIA认证的Aventa临床检测实验室惠及患者，该实验室常规发现其他临床测试忽略的基因融合和重排——这些见解定义了多种癌症的诊断、预后和治疗选择。

Under the leadership of Willis, Arima will build on a decade of discovery-driven research to launch a focused pipeline of clinical assays that expand this technology’s impact..

在威利斯的领导下，阿里马将在十年发现驱动研究的基础上，推出一系列重点临床试验，扩大该技术的影响。

“Arima has spent years perfecting its assays and setting the pace for the field,” said Malek Faham, MD, PhD, chief scientist at Illumina Ventures. “With Tom at the helm, the company is poised to turn that mastery into a definitive diagnostic platform—one that captures the genomic drivers of cancer at every scale and delivers actionable answers for more patients.”.

“Illumina Ventures的首席科学家Malek Faham博士表示：“Arima花费了数年时间完善其检测方法，并为该领域树立了标杆。” “在Tom的领导下，该公司准备将这种技术优势转化为一个决定性的诊断平台——一个能够在各个层面捕捉癌症基因组驱动因素，并为更多患者提供可操作答案的平台。”

Willis brings more than 20 years of company-building experience to Arima. He founded and was CEO at ParAllele BioScience (acquired by Affymetrix) and Sequenta, whose ClonoSEQ® minimal-residual-disease assay became a National Comprehensive Cancer Network (NCCN)-endorsed standard after Sequenta merged with Adaptive Biotechnologies in 2015.

威利斯为阿丽玛带来了超过20年的公司建设经验。他曾创立并担任ParAllele生物科学公司（被Affymetrix收购）和Sequenta的首席执行官，后者的ClonoSEQ®微小残留病检测在2015年Sequenta与Adaptive Biotechnologies合并后成为国家综合癌症网络（NCCN）认可的标准。

Earlier, he directed technology development at the Stanford Genome Technology Center during the Human Genome Project. Willis earned a PhD in Physics from Stanford University and a Bachelor of Science in Physics from Yale University..

早些时候，他在人类基因组计划期间指导了斯坦福基因组技术中心的技术开发。威利斯获得了斯坦福大学的物理学博士学位和耶鲁大学的物理学学士学位。

Founder and former CEO Sid Selvaraj, PhD will continue in an executive role as the president and chief operating officer.

创始人兼前首席执行官Sid Selvaraj博士将继续担任总裁兼首席运营官的执行职务。

“Guiding Arima from concept to a category-defining platform that is already benefiting patients through the Aventa lab has been the privilege of my career,” said Selvaraj. “Tom’s proven ability to take breakthrough tests and turn them into standard of care makes him the ideal leader for our next phase, and I look forward to partnering with him as we collectively attempt to turn cancer into a manageable disease.”.

“引导Arima从概念发展到如今通过Aventa实验室已经让患者受益的定义类别的平台，是我职业生涯的荣幸，”Selvaraj说道。“Tom拥有将突破性测试转化为护理标准的卓越能力，这使他成为我们下一阶段的理想领导者，我期待与他合作，共同致力于将癌症转变为可管理的疾病。”

About Arima Genomics

关于Arima Genomics

Arima Genomics is redefining cancer diagnostics using whole-genome sequence and structure information. Arima’s assays enable a new era of comprehensive, clinically actionable therapy selection insights. The company serves oncologists through its CLIA-certified Aventa clinical testing laboratory in Orlando, Florida, and supports discovery-stage researchers worldwide with advanced kits and informatics.

Arima Genomics正在利用全基因组序列和结构信息重新定义癌症诊断。Arima的检测方法开启了全面且具有临床可操作性的治疗选择新纪元。公司通过其位于佛罗里达州奥兰多的CLIA认证的Aventa临床检测实验室为肿瘤学家提供服务，并通过先进的试剂盒和信息学工具支持全球处于发现阶段的研究人员。

Learn more at arimagenomics.com and aventatest.com, and follow us on LinkedIn and X..

欲了解更多信息，请访问arimagenomics.com和aventatest.com，并在LinkedIn和X上关注我们。

Contact:

联系：

Erin.Davis@arimagenomics.com

Erin.Davis@arimagenomics.com